Establishment Labs Holdings Inc. has appointed Taylor Harris to its Board of Directors, effective June 24, 2026. Mr. Harris will serve until the 2027 annual meeting of shareholders and has been appointed to the Audit Committee and the Nominating and Corporate Governance Committee. He will receive the company's standard non-employee director compensation, including an initial equity grant of $170,000 for new directors and an annual grant of $170,000. Mr. Harris brings over 25 years of experience in corporate finance, executive leadership, and board governance in healthcare, medical technology, and life sciences. His prior roles include CEO of Cutera, Inc., CFO of MyoKardia (acquired by Bristol Myers Squibb for $13.1 billion), CFO of Zeltiq Aesthetics (acquired by Allergan), and CFO of Thoratec Corporation (acquired by St. Jude Medical). He also has over a decade of experience in healthcare equity research and investment banking at JPMorgan Chase & Co. The company issued a press release on June 29, 2026, announcing this director appointment.